Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 4/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.47 |
| ▸ | PDE5A | O76074 | 3/20 | 0.47 |
| ▸ | PDE4A | P27815 | 3/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28940847 | 0.93 | MEN1 (0.50) | CYP2C9CYP2C19CYP1A2CYP19A1CYP2D6 | |
| SCHEMBL2547749 | 0.82 | GRM5 (0.49) | PDE5ACHRNB2CHRNA4MEN1KMT2A | |
| SCHEMBL29407668 | 0.82 | GRM5 (0.49) | PDE5ACHRNB2CHRNA4MEN1KMT2A | |
| SCHEMBL5712881 | 0.79 | CYP2C19 (0.52) | CYP2C9CYP2C19CYP1A2CYP19A1CYP2D6 | |
| SCHEMBL14224809 | 0.79 | CYP2C19 (0.56) | CYP2C9CYP2C19CYP1A2CYP19A1CYP2D6 | |
| SCHEMBL27549301 | 0.79 | KDM4E (0.55) | NPC1RAB9ACHRNB2CHRNA4MAPT | |
| SCHEMBL4318688 | 0.79 | PDE5A (0.46) | CYP2C19CYP1A2CYP2D6PDE5ANPC1 | |
| SCHEMBL9429096 | 0.78 | PPIA (0.45) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL11905535 | 0.78 | CYP2C9 (0.50) | CYP2C9CYP2C19CYP1A2CYP19A1CYP2D6 | |
| SCHEMBL5700226 | 0.78 | CYP2C19 (0.50) | CYP2C9CYP2C19CYP1A2CYP19A1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2863909-B1 | COMBINATIONS COMPRISING 4-METHYL-[1,2,4]TRIAZOLO[4,3-A]QUINOXALINE COMPOUNDS AS PDE 2 INHIBITORS AND PDE 10 INHIBITORS FOR USE IN THE TREATMENT OF NEUROLOGICAL OR METABOLIC DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2020-11-04 | — | — | EP | disclosed |
| WO-2017107979-A1 | TDO2 INHIBITORS | GENENTECH, INC. (US) | 2017-06-29 | — | — | WO | disclosed |
| US-9669035-B2 | Combinations comprising PDE 2 inhibitors such as 1-aryl-4-methyl-[1,2,4]triazolo-[4,3-A]]quinoxaline compounds and PDE 10 inhibitors for use in the treatment of neurological of metabolic disorders | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-06 | — | — | US | disclosed |
| CN-101522674-B | Novel compounds, pharmaceutically acceptable salts as vanilloid receptor antagonist and pharmaceutical composition comprising the compounds | AMOREPACIFIC CORP | 2013-08-21 | — | — | CN | disclosed |
| CN-101522674-A | Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist | AMOREPACIFIC CORP (KR) | 2009-09-02 | — | — | CN | disclosed |
| EP-1270582-B1 | TRIPHENYLPHOSPHINE DERIVATIVES, PALLADIUM OR NICKEL COMPLEXES THEREOF, AND PROCESS FOR PREPARING BIARYL DERIVATIVES | MITSUBISHI RAYON CO (JP) | 2006-08-30 | — | — | EP | disclosed |
| US-6693210-B2 | USING PALLADIUM, NICKEL PHOSPHINE COMPLEX AS CATALYSTS | MITSUBISHI RAYON CO., LTD. (JP) | 2004-02-17 | — | — | US | disclosed |
| US-20030065208-A1 | Using palladium, nickel phosphine complex as catalysts | MITSUBISHI RAYON CO., LTD. (JP) | 2003-04-03 | — | — | US | disclosed |
| EP-1270582-A1 | TRIPHENYLPHOSPHINE DERIVATIVE, PRODUCTION PROCESS THEREFOR, PALLADIUM COMPLEX THEREOF, AND PROCESS FOR PRODUCING BIARYL DERIVATIVE | Mitsubishi Rayon Co., Ltd. (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065208-A1 | Using palladium, nickel phosphine complex as catalysts | PDCD1LG2, PIK3CA, PDCD1 | CYP2C9 2277/4885CYP2C19 1488/4885CYP1A2 2692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.